Melatonin rescues zebrafish embryos from the parkinsonian phenotype restoring the parkin/PINK1/DJ-1/MUL1 network

Journal of Pineal Research

Volumn , Issue , 2016, Pages 96-107

  Díaz Casado, María E ^a,b   Lima, Elena ^a   García, José A ^a,b   Doerrier, Carolina ^a,b   Aranda, Paula ^a,b   Sayed, Ramy K A ^a,c   Guerra Librero, Ana ^a,b   Escames, Germaine ^a,b   López, Luis C ^a,b   Acuña Castroviejo, Darío ^a,b,d  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c Sohag University   (Egypt)

^d HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; mitochondrial complex I; mitochondrial related genes; parkinson's disease; zebrafish

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GAMMA SYNUCLEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MELATONIN; MITOCHONDRIAL PROTEIN; PARKIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; DIENCEPHALON; DRUG ACTIVITY; EMBRYO; EMBRYO DEVELOPMENT; GENE; IMMUNOFLUORESCENCE; LOCOMOTION; MITOCHONDRION; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OLFACTORY BULB; OXIDATIVE STRESS; PARKINSONISM; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ZEBRA FISH;

EID: 84978116690     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12332     Document Type: Article

References (75)

1. Holzschuh J, Ryu S, Aberger F et al. Dopamine transporter expression distinguishes dopaminergic neurons from other catecholaminergic neurons in the developing zebrafish embryo. Mech Dev 2001; 101:237–243.
2. Rink E, Wullimann MF. The teleostean (zebrafish) dopaminergic system ascending to the subpallium (striatum) is located in the basal diencephalon (posterior tuberculum). Brain Res 2001; 889:316–330.
3. Flinn L, Mortiboys H, Volkmann K et al. Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio). Brain 2009; 132:1613–1623.
4. Sallinen V, Kolehmainen J, Priyadarshini M et al. Dopaminergic cell damage and vulnerability to MPTP in Pink1 knockdown zebrafish. Neurobiol Dis 2010; 40:93–101.
5. Braak H, Sandmann-Keil D, Gai W et al. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci Lett 1999; 265:67–69.
6. Braak H, Tk Del, Rub U et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24:197–211.
7. Spillantini MG, Schmidt ML, Lee VM et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388:839–840.
8. Milanese C, Sager JJ, Bai Q et al. Hypokinesia and reduced dopamine levels in zebrafish lacking beta- and gamma1-synucleins. J Biol Chem 2012; 287:2971–2983.
9. Sun Z, Gitler AD. Discovery and characterization of three novel synuclein genes in zebrafish. Dev Dyn 2008; 237:2490–2495.
10. Toni M, Cioni C. Fish synucleins: an update. Mar Drugs 2015; 13:6665–6686.
11. Shimura H, Hattori N, Kubo S et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25:302–305.
12. Valente EM, Abou-Sleiman PM, Caputo V et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304:1158–1160.
13. Clark IE, Dodson MW, Jiang C et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006; 441:1162–1166.
14. Kane LA, Lazarou M, Fogel AI et al. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol 2014; 205:143–153.
15. Kitada T, Tong Y, Gautier CA et al. Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. J Neurochem 2009; 111:696–702.
16. Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron 2015; 85:257–273.
17. Bai Q, Mullett SJ, Garver JA et al. Zebrafish DJ-1 is evolutionarily conserved and expressed in dopaminergic neurons. Brain Res 2006; 1113:33–44.
18. Ariga H, Takahashi-Niki K, Kato I et al. Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev 2013; 2013:683920.
19. Taira T, Saito Y, Niki T et al. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 2004; 5:213–218.
20. Ishikawa S, Taira T, Takahashi-Niki K et al. Human DJ-1-specific transcriptional activation of tyrosine hydroxylase gene. J Biol Chem 2010; 285:39718–39731.
21. Abeliovich A, Flint BM. Parkinsonism genes: culprits and clues. J Neurochem 2006; 99:1062–1072.
22. Van Der Merwe C, Jalali Sefid DZ, Christoffels A et al. Evidence for a common biological pathway linking three Parkinson's disease-causing genes: parkin, PINK1 and DJ-1. Eur J Neurosci 2015; 41:1113–1125.
23. Yun J, Puri R, Yang H et al. MUL1 acts in parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss of PINK1/parkin. Elife 2014; 3:e01958.
24. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006; 7:207–219.
25. Schapira AH, Cooper JM, Dexter D et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54:823–827.
26. Przedborski S, Jackson-Lewis V, Yokoyama R et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A 1996; 93:4565–4571.
27. Lima-Cabello E, Diaz-Casado ME, Guerrero JA et al. A review of the melatonin functions in zebrafish physiology. J Pineal Res 2014; 57:1–9.
28. Acuña-Castroviejo D, Escames G, Venegas C et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci 2014; 71:2997–3025.
29. Venegas C, Garcia JA, Escames G et al. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res 2012; 52:217–227.
30. Acuña-Castroviejo D, Lopez LC, Escames G et al. Melatonin-mitochondria interplay in health and disease. Curr Top Med Chem 2011; 11:221–240.
31. Acuña-Castroviejo D, Martin M, Macias M et al. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res 2001; 30:65–74.
32. Acuña-Castroviejo D, Escames G, Rodriguez MI et al. Melatonin role in the mitochondrial function. Front Biosci 2007; 12:947–963.
33. Martin M, Macias M, Escames G et al. Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. FASEB J 2000; 14:1677–1679.
34. Reiter RJ, Tan DX, Pappolla MA. Melatonin relieves the neural oxidative burden that contributes to dementias. Ann N Y Acad Sci 2004; 1035:179–196.
35. Acuña-Castroviejo D, Coto-Montes A, Gaia MM et al. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1997; 60:L23–L29.
36. Antolin I, Mayo JC, Sainz RM et al. Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res 2002; 943:163–173.
37. Khaldy H, Escames G, Leon J et al. Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion. Neurobiol Aging 2003; 24:491–500.
38. Tapias V, Escames G, Lopez LC et al. Melatonin and its brain metabolite N(1)-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice. J Neurosci Res 2009; 87:3002–3010.
39. Westerfield M. The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio) 5th edn, University of Oregon Press, Eugene, 2007.
40. Macdonald R. Zebrafish immunohistochemistry. Methods Mol Biol 1999; 127:77–88.
41. Sallinen V, Torkko V, Sundvik M et al. MPTP and MPP+ target specific aminergic cell populations in larval zebrafish. J Neurochem 2009; 108:719–731.
42. Barrientos A. In vivo and in organello assessment of OXPHOS activities. Methods 2002; 26:307–316.
43. Birch-Machin MA, Briggs HL, Saborido AA et al. An evaluation of the measurement of the activities of complexes I-IV in the respiratory chain of human skeletal muscle mitochondria. Biochem Med Metab Biol 1994; 51:35–42.
44. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008; 7:97–109.
45. Schapira AH, Cooper JM, Dexter D et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989; 1:1269.
46. Blesa J, Trigo-Damas I, Quiroga-Varela A et al. Oxidative stress and Parkinson's disease. Front Neuroanat 2015; 9:91.
47. Forstermann U, Boissel JP, Kleinert H. Expressional control of the ‘constitutive’ isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998; 12:773–790.
48. Hwang O. Role of oxidative stress in Parkinson's disease. Exp Neurobiol 2013; 22:11–17.
49. Naskar A, Prabhakar V, Singh R et al. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. J Pineal Res 2015; 58:262–274.
50. Wen L, Wei W, Gu W et al. Visualization of monoaminergic neurons and neurotoxicity of MPTP in live transgenic zebrafish. Dev Biol 2008; 314:84–92.
51. Perry VH. Innate inflammation in Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2:a009373.
52. Cardoso SM. The mitochondrial cascade hypothesis for Parkinson's disease. Curr Pharm Des 2011; 17:3390–3397.
53. Sai Y, Zou Z, Peng K et al. The Parkinson's disease-related genes act in mitochondrial homeostasis. Neurosci Biobehav Rev 2012; 36:2034–2043.
54. Anichtchik O, Diekmann H, Fleming A et al. Loss of PINK1 function affects development and results in neurodegeneration in zebrafish. J Neurosci 2008; 28:8199–8207.
55. Chartier-Harlin MC, Kachergus J, Roumier C et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364:1167–1169.
56. Chen YC, Cheng CH, Chen GD et al. Recapitulation of zebrafish sncga expression pattern and labeling the habenular complex in transgenic zebrafish using green fluorescent protein reporter gene. Dev Dyn 2009; 238:746–754.
57. Haque ME, Thomas KJ, D'Souza C et al. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc Natl Acad Sci U S A 2008; 105:1716–1721.
58. Petit A, Kawarai T, Paitel E et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem 2005; 280:34025–34032.
59. Rub C, Schroder N, Voos W. Biochemical properties of the kinase PINK1 as sensor protein for mitochondrial damage signalling. Biochem Soc Trans 2015; 43:287–291.
60. Li W, Bengtson MH, Ulbrich A et al. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS ONE 2008; 3:e1487.
61. Bir A, Sen O, Anand S et al. Alpha-Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson's disease. J Neurochem 2014; 131:868–877.
62. Su LY, Li H, Lv L et al. Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/alpha-synuclein aggregation. Autophagy 2015; 11:1745–1759.
63. Garcia JA, Volt H, Venegas C et al. Disruption of the NF-kappaB/NLRP3 connection by melatonin requires retinoid-related orphan receptor-alpha and blocks the septic response in mice. FASEB J 2015; 29:3863–3875.
64. Guo P, Pi H, Xu S et al. Melatonin Improves mitochondrial function by promoting MT1/SIRT1/PGC-1 alpha-dependent mitochondrial biogenesis in cadmium-induced hepatotoxicity in vitro. Toxicol Sci 2014; 142:182–195.
65. O'Donnell KC, Lulla A, Stahl MC et al. Axon degeneration and PGC-1alpha-mediated protection in a zebrafish model of alpha-synuclein toxicity. Dis Model Mech 2014; 7:571–582.
66. Volt H, Garcia JA, Doerrier C et al. Same molecule but different expression: aging and sepsis trigger NLRP3 inflammasome activation, a target of melatonin. J Pineal Res 2016; 60:193–205.
67. Lopez A, Garcia JA, Escames G et al. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J Pineal Res 2009; 46:188–198.
68. Crespo E, Macias M, Pozo D et al. Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J 1999; 13:1537–1546.
69. Escames G, Leon J, Macias M et al. Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats. FASEB J 2003; 17:932–934.
70. Zhang HM, Zhang Y. Melatonin: a well-documented antioxidant with conditional prooxidant actions. J Pineal Res 2014; 57:131–146.
71. Ozturk G, Akbulut KG, Guney S et al. Age-related changes in the rat brain mitochondrial antioxidative enzyme ratios: modulation by melatonin. Exp Gerontol 2012; 47:706–711.
72. Manchester LC, Coto-Montes A, Boga JA et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res 2015; 59:403–419.
73. Bueler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol 2009; 218:235–246.
74. Brustein E, Saint-Amant L, Buss RR et al. Steps during the development of the zebrafish locomotor network. J Physiol Paris 2003; 97:77–86.
75. Milane L, Trivedi M, Singh A et al. Mitochondrial biology, targets, and drug delivery. J Control Release 2015; 207:40–58.